News
Presentation to include positive clinical results from the Phase 3 SURPASS-ET clinical trial of ropeginterferon alfa-2b-njft for the treatment of essential thrombocythemia (ET) PharmaEssentia USA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback